Fourth development phase: formulation and process testing
Quality risk management applied to pharmaceutical product development
Article REF: PHA3051 V1
Fourth development phase: formulation and process testing
Quality risk management applied to pharmaceutical product development

Authors : Jean-Jacques HOURI, Mélisande BERNARD, Hassane SADOU-YAYE, Bernard DO

Publication date: February 10, 2016 | Lire en français

Logo Techniques de l'Ingenieur You do not have access to this resource.
Request your free trial access! Free trial

Already subscribed?

5. Fourth development phase: formulation and process testing

5.1 Formulation tests

Formulation tests follow on from the tests carried out during the pre-formulation phase, and enable the identification of material attributes with a high risk of impacting on the CQAs of the finished product. A qualitative and quantitative evaluation of the formulas using the experimental design method enables the most suitable formulation to be chosen. The proportion of CMC can influence the finished product's AQA (uniformity of content, dosage and dissolution), since it can affect both the quality of compaction and the breaking strength of tablets during the compression phase.

The selection of the final formulation should take into account the elements summarized below:

  • the difference between...

You do not have access to this resource.
Logo Techniques de l'Ingenieur

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed?


Article included in this offer

"Drugs and pharmaceuticals"

( 125 articles )

Complete knowledge base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

View offer details
Contact us